Condition
Smith-Magenis Syndrome
Total Trials
5
Recruiting
1
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (1)
P 2 (1)
Trial Status
Completed3
Recruiting1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05116904Not ApplicableRecruitingPrimary
Smith Magenis Syndrome and Autism Spectrum Disorders
NCT02776215Phase 1Completed
Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
NCT04768803Unknown
Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity
NCT02231008Phase 2CompletedPrimary
Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS
NCT00004351Completed
Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes
Showing all 5 trials